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Abstract
Introduction: Juvenile idiopathic arthritis (JIA) is an umbrella term for all chronic childhood arthropathies and can
be divided into seven subtypes. It includes the enthesitis related arthritis (ERA) subtype which displays symptoms
similar to ankylosing spondylitis (AS) and juvenile-onset psoriatic arthritis which has similarities to psoriatic arthritis
(PsA) and psoriasis (Ps). We, therefore, hypothesized that two well-established susceptibility loci for AS and Ps,
ERAP1 and IL23R, could also confer susceptibility to these JIA subtypes.
Methods: Single nucleotide polymorphisms (SNPs) in ERAP1 (rs30187) and IL23R (rs11209026) were genotyped in JIA
cases (n = 1,054) and healthy controls (n = 5,200). Genotype frequencies were compared between all JIA cases and
controls using the Cochrane-Armitage trend test implemented in PLINK. Stratified analysis by ILAR subtype was performed.
Results: The ERA subtype showed strong association with ERAP1 SNP (P trend = 0.005). The IL23R SNP showed
significant association in the PsA subtype (P trend = 0.04). The SNPs were not associated with JIA overall or with
any other subtype.
Conclusions: We present evidence for subtype specific association of the ERAP1 gene with ERA JIA and the IL23R
gene with juvenile-onset PsA. The findings will require validation in independent JIA datasets. These results suggest
distinct pathogenic pathways in these subtypes.
Introduction
There is now strong evidence supporting the hypothesis
of common autoimmune genetic susceptibility loci [1].
Ankylosing spondylitis (AS), psoriasis (Ps) and psoriatic
arthritis (PsA) are a group of autoimmune diseases
which share some clinical features and some overlapping
susceptibility loci such as endoplasmic reticulum amino-
peptidase 1 (ERAP1) (formerly known as ARTS1) [2,3]
and the interleukin 23 receptor (IL23R) [2,4,5].
Juvenile idiopathic arthritis (JIA) is an umbrella term for
all chronic childhood arthropathies and can be classified
into seven subtypes on the basis of features present in the
first six months of disease [6]. It includes the enthesitis
related arthritis (ERA) subtype, which displays symptoms
similar to AS and juvenile onset psoriatic arthritis, which
has similarities to psoriatic arthritis and psoriasis. We
have, therefore, hypothesized that the two well-established
susceptibility loci, ERAP1 and IL23R, also confer suscept-
ibility to these JIA subtypes. To this end the most asso-
ciated single nucleotide polymorphism (SNP) within each
of these genes has been selected for genotyping across all
JIA and also analysed stratified by ILAR subtype.
Materials and methods
Subjects
For the analysis of the ERAP1 SNP, DNA was available
for 1,054 UK Caucasian JIA patients (332 males, 715
females) as previously described [7]. JIA cases were
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any medium, provided the original work is properly cited.classified according to ILAR criteria [6]. The numbers gen-
otyped per ILAR subgroup were: Systemic onset (n = 164),
persistent oligoarthritis (n = 297), extended oligoarthritis
(n = 147), rheumatoid factor (RF) negative polyarticular
JIA (n = 215), RF positive polyarticular JIA (n = 68), enthe-
sitis related JIA (n = 63), psoriatic JIA (n = 76) and unclas-
sified (n = 24). For the analysis of the IL23R SNP, there
were an additional 190 JIA cases available, making a total
of 1,244 JIA cases. The numbers genotyped per ILAR
subgroup were: Systemic onset (n = 179), persistent
oligoarthritis (n = 380), extended oligoarthritis (n = 159),
rheumatoid factor (RF) negative polyarticular JIA (n =
259), RF positive polyarticular JIA (n = 76), enthesitis
related JIA (n = 74), psoriatic JIA (n = 93) and unclassified
(n = 24). All individuals were recruited with ethical
approval and provided informed consent (North-West
Multi-Centre Research Ethics Committee (MREC 99/8/
84) and the University of Manchester Committee on the
Ethics of Research on Human Beings).
The control genotyping data were extracted from the
Wellcome Trust case control consortium 2 (WTCCC2)
European Genome-phenome Archive (EGA) website [8],
both SNPs had been genotyped on the Illumina platform
(n = 5,200).
SNP selection
SNPs in IL23R (rs11209026) and ERAP1 (rs30187) pre-
viously associated with AS and Ps were selected for
genotyping.
Genotyping
All SNPs were genotyped, in UK JIA cases, using the
Sequenom iPlex
® MassARRAY platform according to
manufacturer’s instructions (Sequenom, San Diego, CA,
USA [9]). A 90% sample quality control rate and 90%
genotyping success rate was imposed on the analysis.
Statistical analysis
Power calculations were performed using QUANTO [10]
based on the effect sizes reported in previous studies of
these SNPs in AS [2,11]. Calculations assumed a log-
additive model and an alpha value of 0.05. Genotype and
allele frequencies were compared between cases with JIA
and controls using STATA version 9 SE (StataCorp, College
Station, Texas, USA) and PLINK [12]. Associations were
expressed as odds ratios (ORs) and 95% confidence intervals
(CIs). There was a strong prior hypothesis that these SNPs
would be associated with the ERA and PsA subtypes of JIA;
therefore, we performed stratified analysis by ILAR subtype.
Results
SNPs were in Hardy-Weinberg equilibrium (P > 0.05) in
the control cohort.
Neither rs30187 in ERAP1 nor rs11209026 in IL23R
were significantly associated with the total JIA dataset
(P trend = 0.73, OR = 1.03 95% CI 0.92 to 1.14 and P
trend = 0.46, OR = 0.93 95% CI 0.78 to 1.12, respectively).
After stratification by ILAR subtype (Table 1) the ERA
subtype showed strong association with the ERAP1 SNP
(P trend = 0.005, OR = 1.69 95% CI 1.17 to 2.44). For
the IL23R SNP there was significant association in the
psoriatic arthritis subtype (P trend = 0.04, OR = 0.4 95%
CI 0.16 to 0.98) and a trend towards association in the
enthesitis related subtype (P trend = 0.15, OR = 0.52
95% CI 0.21 to 1.28). For both SNPs the association is
in the same direction as in the original studies.
Table 1 Association analysis of IL23R (rs11209026) and ERAP1 (rs30187) SNPs in all JIA and stratified by subtype
IL23R (rs11209026) ERAP1 (rs30187)
ILAR subtype MAF
Cases
MAF
Controls
P Trend OR 95% CI MAF
Cases
MAF
Controls
P Trend OR 95% CI
All JIA 0.06 0.07 0.46 0.93
(0.78 to 1.12
0.34 0.33 0.65 1.02
(0.92 to 1.13
Systemic 0.08 0.07 0.44 1.17
(0.78 to 1.76)
0.35 0.33 0.56 1.07
(0.85 to 1.36)
Persistent oligoarthritis 0.07 0.07 0.85 1.03
(0.77 to 1.39)
0.31 0.33 0.31 0.91
(0.76 to 1.09)
Extended oligoarthritis 0.07 0.07 0.65 1.11
(0.71 to 1.72)
0.34 0.33 0.84 1.03
(0.80 to 1.32)
RF negative polyarthritis 0.06 0.07 0.5 0.88
(0.6 to 1.29)
0.30 0.33 0.19 0.86
(0.70 to 1.07)
RF positive oligoarthritis 0.07 0.07 0.93 0.97
(0.49 to 1.91)
0.39 0.33 0.22 1.26
(0.87 to 1.82)
Enthesitis related arthritis 0.04 0.07 0.15 0.52
(0.21 to 1.28)
0.46 0.33 0.005 1.69
(1.178 to 2.44)
Psoriatic arthritis 0.03 0.07 0.04 0.4
(0.16 to 0.98)
0.38 0.33 0.21 1.24
(0.88 to 1.74)
CI, confidence interval; ERAP1, endoplasmic reticulum aminopeptidase 1; IL23R, interleukin 23 receptor; JIA, juvenile idiopathic arthritis; MAF, minor allele
frequency; OR, odds ratio.
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Investigating the genetic susceptibility loci identified for
clinically related autoimmune diseases has been a very
successful strategy in the search for novel JIA suscept-
ibility loci [7]. Using this approach in this study we have
identified subtype specific effects in JIA.
We found strong association of the ERA subtype with
the ERAP1 SNP. There was no significant association
with any other subtype. However, it should be noted that
the individual subtypes had between 16 and 54% power
to detect an association. The ERAP1 variant, rs30187, is a
non-synonymous SNP, K528R, located in exon 6 of the
gene previously associated with AS [2], with Ps [3] and
PsA (personal communication, Anne Barton), and also
with type 1 diabetes [13]. In a recent fine-mapping study,
multiple SNPs across the region were associated with AS
and they were not able to identify the causal marker from
the genetic data due to the high LD across the region.
Imputation analysis in this dataset found strong associa-
tions for imputed SNPs, including some SNPs in regula-
tory regions which may be good candidates for the causal
SNP. Further studies on how these SNPs affect expres-
sion of ERAP1 are now required [11].
ERAP1 encodes a multifunctional aminopeptidase, but
its role in the pathogenesis in any of the associated dis-
eases has yet to be determined (reviewed in [14]). It
m a yp l a yar o l ei nt r i m m i n gp e p t i d e s ,i nt h ee n d o p l a s -
mic reticulum, for binding to HLA class I molecules
where they are transported to the cell surface for pre-
sentation to T cells. Alternatively it may be important
through its function in cleaving pro-inflammatory cyto-
kine receptors, such as tumour necrosis factor receptor
1 (TNFR1) to generate soluble TNFR1. It is also thought
to play a role in the cleavage of interleukin 1 receptor 2
(IL1R2) and interleukin 6 receptor alpha (IL6Ra), lead-
ing to increased soluble IL1R2 and IL6Ra.
The IL23R SNP showed significant association in the
PsA subtype and a trend towards association in the ERA
subtype, with similar effect sizes in both subtypes, sug-
gesting that the lack of significant association in the
ERA subtype of JIA may just be due to a lack of power
(this subtype had 37% power to detect an association).
IL23R shows association not only with AS, Ps,
PsA [2,4,5], but also with inflammatory bowel disease
[15] and paediatric Crohn’s disease [16]. The SNP
rs11209026 appears to be the primary associated poly-
morphism [17]. It is a non-synonymous SNP, Q381R,
located in exon 5 of the gene. In all cases the minor
allele is associated with protection for developing the
disease. The association of IL23R with these conditions
suggests that the T Helper 17 (TH17) pathway may be
involved in disease pathogenesis. IL23R is also expressed
on other immunological cell types such as macrophages,
natural killer cells and microglia and it is not yet
determined which cell type is affected by the IL23R var-
iant. Therapeutic approaches to inhibiting TH17 cells
are now being investigated that could be useful in the
treatment of juvenile-onset PsA and the ERA subtype
of JIA.
To date it has been very difficult to identify ILAR sub-
type specific effects in JIA due to small sample sizes and
the inevitable loss of power that this entails as well as
the issues of multiple testing. In this case there was a
strong prior hypothesis that ERAP1 and IL23R confer
susceptibility to particular subtypes. However, the
results will require validation in independent datasets.
The lack of association across the other subtypes will
also require further investigation. For the ERAP1 SNP
we had between 16 and 54% power to detect an associa-
tion across the subtypes and for the IL23R SNP we had
between 37 and 95% power to detect an association.
The search for subtype specific effects in JIA is impera-
tive because it will aid in the refinement of the JIA clas-
sification, potentially lead to a better understanding of
subtype specific disease pathogenesis, and ultimately to
the development of more targeted therapies for the spe-
cific subtypes of JIA. It may also be relevant for evaluat-
ing prognosis. Not all children with ERA will go on to
have the complete AS phenotype and it may be that car-
riage of these risk alleles predict progression to axial
involvement and eventual ankylosis [18].
Conclusions
We present evidence for subtype specific association of
the IL23R gene with juvenile-onset PsA and ERAP1
gene with the ERA subtype of JIA. These results suggest
distinct pathogenic pathways in these subtypes.
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